title: The effects of caspofungin and voriconazole in experimental Candida endophthalmitis.
abstract: OBJECTIVE
  To evaluate the efficacy of newly developed antifungal agents caspofungin and voriconazole in Candida albicans endophthalmitis in rabbit eyes.
  
  
  METHODS
  Thirty New Zealand white rabbits were divided into four treatment groups and one control group. One eye of each rabbit was infected by inoculation of 1 x 10(4) CFU/ml of C. albicans. Seventy-two hours after the inoculation, caspofungin 100 microg/0.1 ml in group 1 (n = 6), voriconazole 50 microg/0.1 ml in group 2 (n = 6), amphotericin B 10 microg/0.1 ml in group 3 (n = 6), itraconazole 10 microg/0.1 ml in group 4 (n = 6), and 0.1 ml NaCl 0.9% in control group (n = 6) were injected into the vitreous cavity. Clinical and histopathologic examination scores and microbiological analysis of vitreous aspirates were compared.
  
  
  RESULTS
  There was statistically significant difference in the clinical scores, histopathologic scores, and mean CFU/ml between the treatment and control groups (p < 0.05). In caspofungin and voriconazole groups, histopathologic scores and mean CFU were lower than other treatment groups and control group.
  
  
  CONCLUSIONS
  Intravitreal injection of caspofungin and voriconazole was effective against C. albicans endophthalmitis in this experimental rabbit model.
authors: Department of Ophthalmology, Kocatepe University School of Medicine, Afyon, Turkey. tkusbeci@yahoo.com
authors: Tuncay
authors: T
authors: Kusbeci
authors: Berrin
authors: B
authors: Avci
authors: Zafer
authors: Z
authors: Cetinkaya
authors: Faruk
authors: F
authors: Ozturk
authors: Güliz
authors: G
authors: Yavas
authors: Sitki Samet
authors: SS
authors: Ermis
authors: Umit Ubeyt
authors: UU
authors: Inan
mesh_terms: D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D002176:Candida albicans / Q000254:growth & development; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology; D000077336:Caspofungin; D015169:Colony Count, Microbial; D003315:Cornea / Q000382:microbiology; D004195:Disease Models, Animal; D054714:Echinocandins; D009877:Endophthalmitis / Q000188:drug therapy* / Q000382:microbiology; D015821:Eye Infections, Fungal / Q000188:drug therapy* / Q000382:microbiology; D017964:Itraconazole / Q000627:therapeutic use; D055666:Lipopeptides; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D011817:Rabbits; D014230:Triazoles / Q000627:therapeutic use*; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010456:Peptides, Cyclic; D011743:Pyrimidines; D014230:Triazoles; D017964:Itraconazole; D000666:Amphotericin B; D000077336:Caspofungin; D065819:Voriconazole